This is a preview of subscription content, log in via an institution to check access.
Notes
2015/2016 British pounds
long-acting muscarinic antagonist
Reference
Shah D, et al. Cost-effectiveness of umeclidinium compared with tiotropium and glycopyrronium as monotherapy for chronic obstructive pulmonary disease: a UK perspective. Cost Effectiveness and Resource Allocation 16: No. 17, 10 May 2018. Available from: URL: https://doi.org/10.1186/s12962-018-0101-3
Rights and permissions
About this article
Cite this article
Umeclidinium cost effective for COPD in UK. PharmacoEcon Outcomes News 804, 36 (2018). https://doi.org/10.1007/s40274-018-5000-5
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-018-5000-5